CN1176820A - Red ginseng and hawthorn fruit health-care wine - Google Patents
Red ginseng and hawthorn fruit health-care wine Download PDFInfo
- Publication number
- CN1176820A CN1176820A CN 97117034 CN97117034A CN1176820A CN 1176820 A CN1176820 A CN 1176820A CN 97117034 CN97117034 CN 97117034 CN 97117034 A CN97117034 A CN 97117034A CN 1176820 A CN1176820 A CN 1176820A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- blood
- herbal medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000002789 Panax ginseng Nutrition 0.000 title claims abstract description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 title claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 title claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 title claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 title claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 title claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 title claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 title claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 title claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 title claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 title claims description 6
- 235000013399 edible fruits Nutrition 0.000 title claims description 6
- 240000000171 Crataegus monogyna Species 0.000 title claims 3
- 230000036541 health Effects 0.000 claims abstract description 20
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 230000001737 promoting effect Effects 0.000 claims description 17
- 241000411851 herbal medicine Species 0.000 claims description 14
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 8
- 241000208340 Araliaceae Species 0.000 claims description 7
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 241000219780 Pueraria Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 45
- 239000008280 blood Substances 0.000 abstract description 45
- 230000006870 function Effects 0.000 abstract description 5
- 210000003743 erythrocyte Anatomy 0.000 abstract description 3
- 235000008216 herbs Nutrition 0.000 abstract 2
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 102000015779 HDL Lipoproteins Human genes 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 239000003172 expectorant agent Substances 0.000 description 10
- 230000003419 expectorant effect Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 230000008034 disappearance Effects 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 206010062717 Increased upper airway secretion Diseases 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 7
- 208000026435 phlegm Diseases 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000031226 Hyperlipidaemia Diseases 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 231100001252 long-term toxicity Toxicity 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000002173 dizziness Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 241001092040 Crataegus Species 0.000 description 3
- 208000027219 Deficiency disease Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000031971 Yin Deficiency Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002932 luster Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 229960000716 tonics Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 208000002528 coronary thrombosis Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invented health care wine is prepd. by using spirit as solvent and Chinese medicinal herbs as solute, the Chinese medicinal herbs include Fructus Crataegi, Fructus Hordei Germinatus, Radix Puerariae, Radix Salviae Miltiorrhizae, Rhizome Alismatis, Red Ginseng, Radix Aconiti Kusnezoffii, Rhizoma Polygonati Odorati etc. It possesses the functions of improving the viscosity of blood, lowering the sedimenting of red blood cell and agglomeralion of blood platelet.
Description
The invention belongs to and drink the wine field, relate in particular to a kind of removing food stagnancy stasis of blood alive that has, damp eliminating is reduced phlegm, liver and kidney tonifying, blood lipid regulation improves blood viscosity, the degraded packed cell volume, platelet aggregation, the red ginseng and hawthorn fruit health promoting wine of strengthening by means of tonics function can be prevented and treated cardiovascular and cerebrovascular disease.
Hyperlipidemia is person in middle and old age's a common chronic disease, and along with improving constantly and the further improvement of recipe and the minimizing of body activity of people's living standard, its sickness rate has and increases trend year by year; Hyperlipidemia is atherosclerotic initiating link, and lipid metabolic disorder is again important promoting factor or the risk factor that cardiovascular and cerebrovascular diseases such as " apoplexy ", " coronary heart disease " form; Is 1,85/,100,000/year as acute cerebrovascular disease in China's incidence rate, wherein major part is caused by atherosclerosis, coronary atherosclerotic heart disease is in the crowd of China's generaI investigation more than 30 years old, average prevalence is 6.46%, therefore prevents and treats hyperlipemia and be the effective measures and the important step of disease formation and developments such as the atherosis and apoplexy of prevention of arterial, coronary heart disease.Though transfer the Western medicine of blood fat more at present, clinical efficacy is not fairly obvious, and certain side effect is more or less arranged, and should not take for a long time; The hyperlipidemia traditional Chinese medical science does not have this name of disease, but according to its Clinical symptoms, class belongs to the dizzy of motherland's medical science, phlegm retention, turbid damp, blood stasis disease category, the cardiovascular and cerebrovascular disease that causes thus is equivalent to the thoracic obstruction in motherland's medical science, diseases such as apoplexy, its etiology and pathogenesis are the deficiency in origin and excess in superficiality card, the deficiency in origin person is with YANG deficiency of the spleen and stomach, the hepatic and renal YIN deficiency is main, marking real person is many with the turbid wet Sheng of expectorant, so generally be divided into hepatic and renal YIN deficiency disease clinically, spleen deficiency syndrome, the turbid strongly fragrant resistance disease of expectorant, qi depression to blood stasis disease etc., in recent years, the research of using the Chinese medicine hyperlipidemia development that deepens continuously, obtained certain achievement, but this class preparation is also fewer, indication relatively limits to, the disease type that far can not adapt to clinical complexity, secular clinical in, the utilization Chinese medicine is treated this disease, thinks that the main etiology and pathogenesis of this disease formation and development is that to have a liking for food sweet, rich and fatty diet, so that indigestion, help the wet impairment of the spleen, the dysfunction of the spleen, turbid damp is detained, be condensed into expectorant, give birth in the stagnation of phlegm venation, blood stasis, the expectorant stasis of blood is fought mutually, in the sediment vein, make and give birth to fat.From social survey, know, many people want to control the absorption of pure wine savoury very much, but owing to reasons such as work relationship, social communication and individual's hobbies, this hope is difficult to realize, thereby wish that a kind of style that had both kept Chinese liquor can be arranged, can prevent that again the medicine of curing hyperlipemia comes out.And traditional drugs wine and women-sensual pursuits pool is muddy, the vinosity bitterness, and mouthfeel is poor; Shortcomings such as consumer be difficult for to accept, and what disease traditional medicated wine ubiquity and all control, and function is indeterminate.
The object of the present invention is to provide a kind of red ginseng and hawthorn fruit health promoting wine that utilizes Chinese herbal medicine formula and keep liquor flavor, reach sweet, sweet, soft, continuous, clean, long times of aftertaste, clarity is strong, color and luster is vivid, the characteristics that sweet-smelling overflows are used for treating the hyperlipidemia due to the resistance of the phlegm-damp stasis of blood, take place to prevent and treat caused apoplexy of atherosclerosis and coronary heart disease.
The object of the present invention is achieved like this: be solvent with Chinese liquor, Chinese herbal medicine is a solute, and wherein the Chinese herbal medicine composition is: Fructus Crataegi, Fructus Hordei Germinatus, Radix Puerariae, Radix Salviae Miltiorrhizae, Poria, Rhizoma Alismatis, Radix Ginseng Rubra, Radix Polygoni Multiflori and Rhizoma Polygonati Odorati.
Wherein the Chinese herbal medicine component is: with 32 degree Chinese liquor is solvent, Chinese herbal medicine is a solute, Chinese herbal medicine content is 12% (percentage by weight) in per 1000 milliliters of Chinese liquor, wherein 22 parts of Fructus Crataegi, 14 parts of Fructus Hordei Germinatus, 14 parts of Radix Puerariaes, 14 parts of Radix Salviae Miltiorrhizaes, 11 parts of Poria, 11 parts of Rhizoma Alismatis, 9 parts of Radix Ginseng Rubra, 14 parts of Radix Polygoni Multiflori, 11 parts of Rhizoma Polygonati Odorati.
The present invention compares with traditional medicated wine and health promoting wine has following several advantage:
1, traditional drugs wine and women-sensual pursuits pool is muddy, compares with traditional medicated wine, and it is strong that the present invention has clarity, the characteristics that color and luster is vivid, traditional drugs vinosity bitterness, mouthfeel is poor, and consumer is difficult for accepting, it is sweet, sweet, soft, continuous, clean that the present invention has, the characteristics that long times of aftertaste, sweet-smelling overflow, this health promoting wine definite functions is single-minded, at hyperlipidemia, the generation of control cardiovascular and cerebrovascular disease.
2, have the removing food stagnancy stasis of blood alive, damp eliminating is reduced phlegm, liver and kidney tonifying, blood circulation and channel invigorating, blood lipid regulation improves blood viscosity, the degraded packed cell volume, platelet aggregation, strengthening by means of tonics, effects such as enhance immunity systemic-function, clinical observation 507 examples, total effective rate is 85%, matched group 220 examples, total effective rate are 70%, the present invention and the fat regulating tablet therapeutic equivalence (P＞0.05) that lengthens one's life, acute and the long term toxicity test through animal is not all found toxic and side effects again.
3, Fructus Crataegi " long-pending, the dissipating blood stasis blood that helps digestion is controlled the long-pending lump in the abdomen of meat, phlegm retention " in the prescription, " blood stasis dispelling blood and do not hinder fresh blood, dissipating depression of QI gas and do not hinder healthy energy " are so that stand is monarch; Fructus Hordei Germinatus " help digestion, expectorant drink, broken lump in the abdomen "; Radix Puerariae " evacuation of pus removing blood stasis "; Radix Salviae Miltiorrhizae " blood circulation promoting and blood stasis dispelling ", this three flavor is minister, auxilliary altogether monarch drug increases its consumer product dredge stasis, the power of blood circulation promoting and blood stasis dispelling; Poria " strengthening the spleen stomach function regulating, eliminating dampness and diuresis " also is a minister, altogether the principal drug assistance eliminating dampness and resolving phlegm.After middle age, body constitution becomes to declining, so assistant is got Radix Ginseng Rubra and strengthened the spleen and stomach with the product of Radix Ginseng Rubra, Radix Polygoni Multiflori, beautiful product, makes the strong fortune of temper, and sputum is not given birth to, Radix Polygoni Multiflori nourishing the liver and kidney, Rhizoma Polygonati Odorati yin nourishing profit body; Chinese liquor has the merit of " property that lightly floats is drawn and made the efficacy of a drug sick institute that goes directly, and strengthens blood circulation and channel invigorating "; Modern pharmacological research confirms, Fructus Crataegi, Rhizoma Alismatis, Radix Polygoni Multiflori have and reduce serum cholesterol, triglyceride in various degree and alleviate effect such as atherosclerosis; Fructus Crataegi, Radix Puerariae, Radix Salviae Miltiorrhizae has expansion heart and brain tremulous pulse again respectively, increase groundwater increment, improve partial nutrition supply, prevent cytopathy, alleviate erythrocyte, platelet aggregation, improve blood viscosity, the effect that stops microthrombusis, an amount of drinking white spirit can be had an effect to cholesterol by high density lipoprotein (HDL), HDL gets rid of cholesterol after tremulous pulse transports liver to, thereby prevents accumulation of cholesterol and arteriosclerosis takes place, and ethanol can reduce biologically active pdgf simultaneously, platelet aggregation is suppressed, and consequently coronary artery thrombosis reduces and prevents myocardial infarction.
4, clinical research:
One, physical data
Clinical patient's 727 examples of observing altogether of first and second phase, experimental group 507 examples wherein, matched group 220 examples.Inpatient 152 examples in the experimental group, outpatient's 355 examples.Man's 278 examples, women 229 examples.Age, (X ± SD) was 53.95 ± 7.6 years old, the course of disease 3 ± 1.8 years.Inpatient's 36 examples in the matched group, outpatient's 184 examples.Man's 107 examples, women 113 examples.Age, (X ± SD) was 55.3 ± 8.4 years old, the course of disease 3.3 ± 1.7 years.Two groups of data have comparability.
Two, case choice criteria
(1) diagnostic criteria: formulate with reference to " up-to-date domestic and international disease treatment standard ".
(1), Western medicine diagnose standard: serum cholesterol 〉=6.54 MMOL/L, triglyceride 〉=1.58 MMOL/L, high density lipoprotein: man≤1.03 MMOL/L, woman≤1.16 MMOL/L.Meet person of above-mentioned standard, under the situation that keeps normal diet, the blood sampling secondary is measured blood fat in two weeks, and two times result men and women patient all up to specification can be as being tried case.
(2), tcm diagnosis: hyperlipemia Chinese medicine does not have this name of disease, but clinical symptoms in view of the above, and class belongs to disease scopes such as " dizzy ", " expectorant is turbid ", " blood stasis " of motherland's medical science.
(3), differential diagnosis in tcm standard: with reference to " Diagnostics of Chinese Medicine ", " Chinese Internal Medicine " and " Chinese traditional treatment endocrine metabolism disease ".This wine is mainly used in turbid syndrome of blood stasis of expectorant and blood stasis due to qi deficiency disease in the hyperlipemia.
The turbid Blood stasis of expectorant: headache, dizzy, breast gastral cavity painful abdominal mass is vexed, the figure is fat, purplish tongue is dark or petechia, greasy fur, rolling pulse are arranged.
Syndrome of blood stasis due to qi deficiency: the lazy speech of breathing hard, numb limbs and tense tendons, unconsciously sweat and tire, purplish tongue are dark or petechia is arranged, corpulent tongue is big or light red tongue, deficient pulse is unable or deep-thready pulse is puckery.
(2) include the case standard in:
All ages that meets hyperlipemia diagnostic criteria and differential diagnosis in tcm standard are 35-65 year patient.
(3) exclusion standard:
(1), the age below 35 years old or over-65s, gestation or women breast-feeding their children, to the wine allergy sufferers.
(2), suffered from once in half a year that acute cardiac muscle stalk is cold, cerebrovascular accident, severe trauma, capital operation, the nephrotic syndrome, hypothyroidism, acute and chronic liver and gall diseases, diabetes merge hyperlipemia, psychosis and clinicist and think other patients that should not be tried according to pharmacology, toxicological study result.
(3), medication maybe can't not judged curative effect in accordance with regulations, or data not congruent affect the treatment evaluation or safety judgement person.
(4), the drug-induced hyperlipemia and the subtype hypercholesterolemiapatients patients of isozygotying.
(5), using heparin, thyroid curative and its to divide influence the patient of blood lipid metabolism medicine and in nearly two months and mistake other patient that blood refers to measure falls.
Three, observation index
(1) safety observation
(1), general health check-up project:
(2), blood, urine, just routine test;
(3), the heart, liver, kidney function test.
(2) health giving quality observation
(1), symptom, sign and TCM Syndrome Type clinical change.
(2), lab testing: 1. blood fat: mainly comprise cholesterol, triglyceride, high density lipoprotein; 2. hemorheology: comprise mainly that whole blood viscosity is lowly cut, the whole blood viscosity height is cut, packed cell volume, platelet electrophoresis time.
Four, test method
Oral health promoting wine of experimental group every day 3 times, each 30-50ML, oral meal.
The oral fat regulating tablet that lengthens one's life of matched group (production of Anyang the 3rd pharmaceutical factory), each 0.3 * 5, every day 3 times, oral meal is 30 days the course of treatment.
Five, curative effect determinate standard
(1) produce effects: clinical symptom disappearance or basic the disappearance, or severe becomes slightly.Cholesterol descends 〉=20%, and triglyceride descends 〉=40%, high density lipoprotein rising 〉=0.258 MMOL/L.
(2) effective: clinical symptom relief or moderate become slightly, and severe becomes moderate.Cholesterol descends＞10%, but＜20%; Triglyceride descends＞20%, but＜40%; High density lipoprotein rising＞0.1 MMOL/L, but＜0.258 MMOL/L.
(3) invalid: as not reach effective standard person.
(4) worsen: cholesterol raises 〉=10%; Triglyceride raises 〉=10%; High density lipoprotein decline 〉=0.1 MMOL/L, and the clinical symptoms person of increasing the weight of.
Six, statistical procedures outline
The enumeration data X that clinical summary is gone out
2Check; Measurement data is checked with T; Ranked data are checked with the Redit analytic process.
Seven, result
(1) curative effect of medication relatively
Two groups of curative effects compare (example)
Add up to the produce effects enabledisable to worsen X P
Experimental group 183 57 102 20 4 blood stasis due to qi deficiency diseases 2.51 0.05
Matched group 66 22 23 14 7
The turbid Blood stasis 0.83 0.05 of experimental group 324 129 143 41 11 expectorant
Matched group 154 67 42 31 14
Experimental group 507 186 245 61 15 total effectses 4.16 0.95
Matched group 220 89 65 45 21
The result shows: the effective percentage of experimental group blood stasis due to qi deficiency disease is 86.89%, and the turbid Blood stasis effective percentage of expectorant is 83.95%, and total effective rate is 85%, experimental group and contrast there was no significant difference.(P＞0.05)。
(2) symptom and sign disappearance situation
Two groups of cardinal symptoms and sign disappearance situation be (example) relatively
The test group control group is controlled precedent and is counted the disappearance disappearance rate and control precedent and count 167 50 29.94 56 27 48.21 1.64＞0.05 liang of group of dizzy 490 429 87.55 190 138 72.63 2.41＞0.05 forgetful 345 247 71.86 169 132 78.10 0.33＞0.05 dreaminess 238 152 63.86 117 87 74.35 0.91＞0.05 extremity numbness, 339 314 92.63 132 110 83.33 0.69＞0.05 chest gastral cavity ruffian of disappearance disappearance rate X P vexed 259 222 85.71 88 73 82.95 0.06＞0.05 shortness of breath and fatigue 329 299 87.84 195 129 66.15 1.72＞0.05 bitter taste symptom and with sign better improvement is arranged all, comparison there was no significant difference between group. (P＞0.05) is to the blood fat situations of influencing before and after two groups of treatments of blood fat relatively (X ± SD, mmol) (three)
Example Tch TG HDL
Experiment 507 6.54 ± 1.56 5.50 ± 1.36** 2.44 ± 1.04 1.73 ± 0.66** 1.09 ± 0.41 1.10 ± 0.40* contrasts 220 6.48 ± 1.48 5.39 ± 1.52** 2.45 ± 1.06 1.69 ± 0.74** 1.08 ± 0.44 1.15 ± 0.46* before and after before and after before and after the number
Annotate: * represents P＜0.05, and * * represents P＜0.01.
Two groups all have reduction Tch, TG, and the effect of rising HDL has notable difference before and after the treatment, but comparing difference is not remarkable between group.
(4) to hemorheological influence
Hemorheology comparison before and after two groups of treatments (X ± SD)
Example whole blood contrast viscosity (height is cut) packed cell volume (%)
Experiment 507 5.82 ± 0.97 4.81 ± 0.92** 52.74 ± 7.22 46.07 ± 6.66** contrast 220 5.58 ± 1.15 5.07 ± 1.31** 49.62 ± 8.74 44.58 ± 8.10** notes before and after before and after the number: on behalf of P＜0.05 * *, * represent P＜0.01
Two groups all have the effect that reduces whole blood contrast viscosity and packed cell volume, equal notable difference before and after the treatment, but comparing difference is not remarkable between group.
(5) safety is observed
Have a blood test before and after the experimental group patient routine and liver function, no abnormal reaction takes place, and except that seldom a part of patient can not accept medicated wine, does not find untoward reaction.
5, the long term toxicity test of wine of the present invention:
Summary: in the time of 60 days, do not produce cumulative toxicity with 11.25g and 22.5g/kg dosage product continuous oral of the present invention for rat.
One, purpose:
Understand the long-term oral the present invention of rat and can produce cumulative toxicity, thereby provide reliable basis for clinical safe medication.
Two, medicine:
The present invention: the sundown transparency liquid, herbal mixture alcohol formulations, liquor strength are 12%, excipient is 33 ° of fermented wine.The highest clinical usual amounts is 150ml/ day, provides the pure medicinal liquid that goes of 1.5g/ml to use for experiment by needs.
Three, animal:
Healthy Wlstar kind outbreeding system rat, body weight 90-110g; The male and female dual-purpose, female for not producing and not having pregnantly, provide by Henan Province's Experimental Animal Center.Conventional feed is fed, and amount of drinking water is not limit, and the experiment room temperature is 22～25 ℃.
Three, grouping and method:
80 animals are divided into four groups at random, 20 every group, male and female half and half.
1, blank group: distilled water, 1.5ml/100g/d * 60lg.
2, excipient matched group: 33 ° of fermented wine are with 6 times of distilled water dilutings; 1.5ml/100d * 60lg.
3, low dose group of the present invention: 11.25g/kg, 1.5g/ml goes pure liquid with 1 times of distilled water diluting, 1.5ml/100g/d * 60lg, be equivalent to clinical plan consumption 37.5 times.
4, high dose group of the present invention: 22.5g/kg, 1.5g/ml removes pure liquid, and 1.5ml/100g/d * 60lg is equivalent to 75 times of clinical plan consumption.
More than four groups of equal per os gastric infusions, continuous 2 months (irritating stomach weekly 6 days), the situations such as activity, appetite, hair and Excreta of observing each Mus every day were weighed once in per 10 days, and change to adjust irritated stomach dosage with body weight.
Each group is got animal eye socket when medication finishes of half quantity and is got blood, checks hemogram (platelet, erythrocyte, hematochrome, leukocyte and classification thereof) and liver (SGPT), kidney (BUN) function.
Adopt the same period cervical vertebra method that pulls to put to death animal, dissect, each main organs situation of perusal, and get brain, the heart, lung, liver,spleen,kidney, stomach, small intestinal and ovary (or testis) tissue, 10% formaldehyde fixed is done the pathology histological examination.Surplus animal is 10 heaven-made same processing after drug withdrawal.
Five, result:
(1) ordinary circumstance: blank group and medication treated animal are in the observation period during medication and after the drug withdrawal, ordinary circumstance is good, outward appearance, behavioral activity are no abnormal, but it is active slightly that the fermented wine treated animal shows, each group does not all have diarrhoea and dead, its body weight has a net increase of the gram number and compares no difference of science of statistics (P＞0.05) with the blank group, the results are shown in Table 1.
(2) blood routine examination of each medication group and liver (SGPT), kidney (BUN) the functional check difference of comparing with the blank group that there are no significant.P＞0.05 the results are shown in Table 2, table 3.
(3) each main organs of animal is through check pathological section, and is all no abnormal.
Six, conclusion:
When giving rat with the continuous irrigation stomach of the present invention of 11.25/kg in the time of 60 days (be equivalent to respectively clinical plan consumption 37.5 times and 75 times), do not find toxic reaction, point out this medicinal liquid to take for a long time and do not produce cumulative toxicity.Table (1) this health promoting wine long term toxicity test is to the influence of the weight of animals
Dosage and method gonosome heavy (g) (X ± SD) have a net increase of body weight (g) P value group g/kg/g * 60ig X ± SD (with empty day matched group than)
Other 0 day 30 days 60 days
Distilled water ♂ 96.00 ± 14.60 209.00 ± 20.03 268.00 ± 20.03 172.00 ± 22.74 blank group 15ml
♀ 101.00±11.41 198.50±17.79 239.50±19.96 138.50±15.41
Dilute 6 times of ♂ 97.00 ± 15ml33 ° of fermented wine ♀ 95.50 of 8.09 211.00 ± 14.98 276.00 ± 20.00 179.00 ± 21.91＞0.05 excipient matched groups ± 31.25 196.20 ± 24.49 233.60 ± 18.58 138.50 ± 26.67＞0.05
Health promoting wine 11.25 low dose group ♀ 101.00 ± 17.18 199.50 ± 20.45 262.86 ± 17.54 161.86 ± 16.30＞0.05, ♂ 102.00 ± 24.66 214.50 ± 17.89 284.50 ± 23.96 182.50 ± 21.08＞0.05
♂ 112.00 ± 24.50 221.70 ± 19.32 296.20 ± 10.26 184.29 ± 19.63＞0.05 health promoting wine 22.5 high dose group ♀ 100.00 ± 18.16 195.60 ± 17.00 255.00 ± 12.36 155.00 ± 24.79＞0.05 table (2) these health promoting wine are to the blood picture influence of rat long term toxicity test (X ± SD)
Dosage and method Hb RBC Plat WBC leukocyte differential count (%) group g/kgd * 60 (g/L) are (10/L) (10/L) lymph neutrality (10/L)
♂ 141.24 ± 9.61 11.90 ± 0.82 728.36 ± 30.25 15.97 ± 3.91 82.51 ± 5.10 17.44 ± 5.10 blank group distilled water
15ml ♀ 133.53±8.26 11.48±1.12 646.45±18.29 16.65±4.82 78.48±5.97 21.64±5.97
♂ 146.17 ± 132.00 ± 11.92 12.02 ± 1.46 865.05 ± 49.77 15.58 ± 3.90 80.61 ± 7.93 19.37 ± 7.93 health liquor ♂ 144.83 ± 15.29 13.29 ± 4.87 725.67 ± 120.48 16.72 ± 4.05 84.59 ± 7.73 15.57 ± 1.73 of 6.47 11.74 ± 1.83 698.88 ± 101.12 18.97 ± 2.26 82.67 ± 6.55 17.34 ± 6.55 excipient control groups, 6 times 33 ° bent wine 15ml ♀ of dilution
11.25 low dose group 15ml ♀ 140.17 ± 10.29 11.54 ± 2.96 887.38 ± 64.70 16.85 ± 2.57 81.24 ± 14.36 18.76 ± 4.36 a health promoting wine ♂ 152.93 ± 11.58 11.75 ± 2.11 790.12 ± 118.03 17.87 ± 3.31 80.32 ± 5.86 19.64 ± 5.76
22.50 high dose group ♀ 144.33 ± 9.58 13.90 ± 1.52 698.67 ± 102.79 18.57 ± 6.96 82.07 ± 10.01 18.11 ± 10.01 table (3) this health promoting wine long term toxicity tests to motion liver, renal function influence group dosage and method SGPT (
H) BUN (mmol/L)
G/kg/d * 60lg is ((the blank group distilled water ♂ 48.18 ± 19.14 7.92 ± 1.44 of X ± SD) of X ± SD) not
15ml ♀ 47.31 ± 47.44 ± 16.07 7.98 ± 1.40 health liquor 22.50 ♂ 49.24 ± 15.94* of 6.99 ± 1.14*33 ° of bent wine 15ml ♀ of 21.02 8.13 ± 0.97 excipient control group distilled water ♂, 51.64 ± 22.65*, 45.83 ± 18.54 7.92 ± 0.88 health liquor 11.25 ♂ 46.76 ± 31.18*, 8.21 ± 0.61* low dose group ♀, 8.11 ± 0.96* high dose group ♀ 49.80 ± 29.23 7.24 ± 1.58
Compare with the blank group: * P＞0.05
The invention will be further described below in conjunction with embodiment.
With 32 degree Chinese liquor is solvent, Chinese herbal medicine is a solute, Chinese herbal medicine content is 12% (percentage by weight) in per 1000 milliliters of Chinese liquor, wherein Fructus Crataegi 22g, Fructus Hordei Germinatus 14g, Radix Puerariae 14g, Radix Salviae Miltiorrhizae 14g, Poria 11g, Rhizoma Alismatis 11g, Radix Ginseng Rubra 9g, Radix Polygoni Multiflori 14g, Rhizoma Polygonati Odorati 11g.Above-mentioned nine flavor Chinese herbal medicine pulverizing backs are added in the 35 degree Chinese liquor, flooded 30-40 days, filter, the medicinal residues squeeze and filter, adding proper honey, Ovum Gallus domesticus album are blent, and leave standstill all after-filtration, packing.
Claims (2)
1, a kind of red ginseng and hawthorn fruit health promoting wine is characterized in that: be solvent with Chinese liquor, Chinese herbal medicine is a solute, and wherein the Chinese herbal medicine composition is: Fructus Crataegi, Fructus Hordei Germinatus, Radix Puerariae, Radix Salviae Miltiorrhizae, Poria, Rhizoma Alismatis, Radix Ginseng Rubra, Radix Polygoni Multiflori and Rhizoma Polygonati Odorati.
2, a kind of red ginseng and hawthorn fruit health promoting wine according to claim 1, it is characterized in that: the Chinese herbal medicine component is: with 32 degree Chinese liquor is solvent, Chinese herbal medicine is a solute, Chinese herbal medicine content is 12% (percentage by weight) in per 1000 milliliters of Chinese liquor, wherein 22 parts of Fructus Crataegi, 14 parts of Fructus Hordei Germinatus, 14 parts of Radix Puerariaes, 14 parts of Radix Salviae Miltiorrhizaes, 11 parts of Poria, 11 parts of Rhizoma Alismatis, 9 parts of Radix Ginseng Rubra, 14 parts of Radix Polygoni Multiflori, 11 parts of Rhizoma Polygonati Odorati.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97117034A CN1063649C (en) | 1997-09-26 | 1997-09-26 | Red ginseng and hawthorn fruit health-care wine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN97117034A CN1063649C (en) | 1997-09-26 | 1997-09-26 | Red ginseng and hawthorn fruit health-care wine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1176820A true CN1176820A (en) | 1998-03-25 |
| CN1063649C CN1063649C (en) | 2001-03-28 |
Family
ID=5174293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN97117034A Expired - Fee Related CN1063649C (en) | 1997-09-26 | 1997-09-26 | Red ginseng and hawthorn fruit health-care wine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1063649C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318072C (en) * | 2004-07-20 | 2007-05-30 | 路开发 | Anti-senility oral liquor |
| CN101323828B (en) * | 2008-08-01 | 2011-11-30 | 赵月政 | Hawthorn wine |
| CN102988838A (en) * | 2012-12-17 | 2013-03-27 | 青岛汉河药业有限公司 | Chinese medicinal composition for treating hyperlipidemia |
| CN108434382A (en) * | 2018-05-28 | 2018-08-24 | 江苏苏南药业实业有限公司 | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof |
| CN108785526A (en) * | 2018-09-12 | 2018-11-13 | 聂聪忠 | A kind of Chinese medicine composition and its beverage and preparation method for preventing coronary heart disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1029081C (en) * | 1988-01-15 | 1995-06-28 | 中国人民解放军第六十九医院 | Productive method for Chinese Cpd. medicine "Sang-ji-Dan" |
| CN1067179A (en) * | 1992-06-17 | 1992-12-23 | 吴守仓 | Prescription of hypolipidemic drug |
-
1997
- 1997-09-26 CN CN97117034A patent/CN1063649C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1318072C (en) * | 2004-07-20 | 2007-05-30 | 路开发 | Anti-senility oral liquor |
| CN101323828B (en) * | 2008-08-01 | 2011-11-30 | 赵月政 | Hawthorn wine |
| CN102988838A (en) * | 2012-12-17 | 2013-03-27 | 青岛汉河药业有限公司 | Chinese medicinal composition for treating hyperlipidemia |
| CN108434382A (en) * | 2018-05-28 | 2018-08-24 | 江苏苏南药业实业有限公司 | It is a kind of to be used to treat pharmaceutical composition of myocardial infarction and preparation method thereof |
| CN108785526A (en) * | 2018-09-12 | 2018-11-13 | 聂聪忠 | A kind of Chinese medicine composition and its beverage and preparation method for preventing coronary heart disease |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1063649C (en) | 2001-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101406677B (en) | Medicinal liquor having function for warming and invigorating kidney yang | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN108567913A (en) | A kind of drug and preparation method thereof for treating diabetes | |
| CN1228074C (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN109771578A (en) | The composition for preventing and treating diabetes and complication | |
| CN108771239A (en) | A kind of strengthening the spleen and stomach herbal paste and preparation method thereof | |
| CN1063649C (en) | Red ginseng and hawthorn fruit health-care wine | |
| CN103705796B (en) | A kind of pharmaceutical composition for the treatment of diarrhoea and preparation method thereof | |
| CN118526548A (en) | Traditional Chinese medicine composition for treating sarcopenia of old people and preparation method and application thereof | |
| CN101062326A (en) | Chinese traditional combination having anti-fatigue function | |
| CN103721187A (en) | Blood-circulation-promoting and blood-fat-reducing pill for treating hyperlipemia and preparation method of pill | |
| CN1299732C (en) | Traditional Chinese medicine preparation for treating fatty liver | |
| CN102274428B (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN1242766C (en) | Medicine for preventing and treating chronic exhaustion syndrome and preparing method thereof | |
| CN1276764C (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating iron-deficiency anemia | |
| CN1085546C (en) | Medicine for treating coronary heart disease, arteriosclerosis and hypertension | |
| CN1233416C (en) | Compound pepsin powder for treating child dyspepsia and its preparation method | |
| CN1253188C (en) | Medicine for treating hypertension and its preparing process | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN103948666B (en) | Preparation method of Tibetan medicine for treating diabetes | |
| CN1850265A (en) | Chinese medicine for treating nephrosis Yang deficiency syndrome | |
| CN107669941A (en) | A kind of Chinese medicinal preparation method for improving insulin resistance | |
| CN107137542A (en) | A kind of pharmaceutical composition of reducing blood lipid | |
| CN105832925A (en) | Traditional Chinese medicine composition for treating hyperlipidaemia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |